title: Herpes zoster and subsequent risk of cancer: a population-based study.
abstract: BACKGROUND
  In this cohort study, we investigated whether a diagnosis of herpes zoster (HZ) was associated with a higher risk of subsequent cancer as compared with the Taiwanese general population.
  
  
  METHODS
  Data were obtained from the Taiwan National Health Insurance Research Database. In total, 38 743 patients who were aged 50 years or older and had received ambulatory care for HZ between 1997 and 2006 were identified as the study cohort; 116 229 age- and sex-matched patients without HZ were included as the comparison cohort. We used Cox proportional hazards regression models to estimate the hazard ratios (HRs) for subsequent cancer, after controlling for potential confounders.
  
  
  RESULTS
  The HR for subsequent cancer varied according to time since HZ diagnosis. The HR was 1.58 (95% CI, 1.38-1.80) within the first year, 1.30 (95% CI, 1.15-1.46) between 1 and 2 years, 1.10 (95% CI, 0.98-1.24) between 2 and 3 years, 1.02 (95% CI, 0.91-1.15) between 3 and 4 years, and 1.08 (95% CI, 0.96-1.21) between 4 and 5 years. The risk of subsequent cancer, particularly lung cancer, was significantly higher during the first 2 years after initial diagnosis of HZ.
  
  
  CONCLUSIONS
  Our findings suggest that an HZ diagnosis is a marker of occult malignancy, particularly in lung cancer. The HRs for cancer decreased gradually over time and were no longer significant after 2 years of follow-up, which indicates that the association between HZ and cancer is likely due to detection bias.
authors.affiliation: Department of Pharmacology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors.forename: Hui-Fen
authors.initials: HF
authors.lastname: Chiu
authors.forename: Brian K
authors.initials: BK
authors.lastname: Chen
authors.forename: Chun-Yuh
authors.initials: CY
authors.lastname: Yang
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D016208:Databases, Factual; D005260:Female; D005500:Follow-Up Studies; D006562:Herpes Zoster / Q000150:complications / Q000175:diagnosis*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology* / Q000821:virology; D018570:Risk Assessment; D013624:Taiwan / Q000453:epidemiology; D013997:Time Factors
references.citation: Ophthalmology. 2011 Jun;118(6):1076-81
references.pmid: 21232800
references.citation: N Engl J Med. 1982 Aug 12;307(7):393-7
references.pmid: 6979711
references.citation: N Engl J Med. 1983 Dec 8;309(23):1434-40
references.pmid: 6195526
references.citation: Arch Dermatol Res. 1987;279 Suppl:S52-4
references.pmid: 2959212
references.citation: J Am Geriatr Soc. 1971 Jun;19(6):495-504
references.pmid: 5094651
references.citation: Viral Immunol. 2003;16(3):243-58
references.pmid: 14583142
references.citation: Neurology. 2010 Mar 9;74(10):792-7
references.pmid: 20200348
references.citation: J Investig Dermatol Symp Proc. 2001 Dec;6(3):183-7
references.pmid: 11924825
references.citation: Diabetes Care. 2010 Jul;33(7):1674-85
references.pmid: 20587728
references.citation: N Engl J Med. 2005 Jun 2;352(22):2266-7
references.pmid: 15930416
references.citation: South Med J. 1995 Nov;88(11):1089-92
references.pmid: 7481976
references.citation: Br J Gen Pract. 2005 Feb;55(511):102-7
references.pmid: 15720930
references.citation: Br J Haematol. 1999 Jan;104(1):144-51
references.pmid: 10027727
references.citation: J Am Acad Dermatol. 1984 Sep;11(3):480-2
references.pmid: 6480952
references.citation: Acta Derm Venereol. 2009 Nov;89(6):612-6
references.pmid: 19997693
references.citation: Br J Cancer. 2004 Oct 4;91(7):1275-9
references.pmid: 15328522
references.citation: J Clin Epidemiol. 1992 Jun;45(6):613-9
references.pmid: 1607900
references.citation: Immunity. 2004 Aug;21(2):137-48
references.pmid: 15308095
references.citation: Br Med J. 1955 Nov 5;2(4948):1106-9
references.pmid: 13260671